Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 7/20 | 0.48 |
| ▸ | PDE6C | P51160 | 1/20 | 0.45 |
| ▸ | ESRRB | O95718 | 4/20 | 0.40 |
| ▸ | ESRRA | P11474 | 4/20 | 0.40 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16410984 | 0.88 | PDE5A (0.57) | PDE5APDE6CACHEMEN1KMT2A | |
| SCHEMBL17792397 | 0.86 | PDE5A (0.47) | PDE5APDE6CACHE | |
| SCHEMBL16403007 | 0.83 | PDE5A (0.63) | PDE5APDE6CACHEMEN1KMT2A | |
| SCHEMBL16403369 | 0.82 | PDE5A (0.61) | PDE5APDE6C | |
| SCHEMBL16403857 | 0.82 | PDE5A (0.61) | PDE5APDE6C | |
| SCHEMBL16411004 | 0.82 | PDE5A (0.55) | PDE5APDE6C | |
| SCHEMBL17796017 | 0.76 | PDE5A (0.85) | PDE5APDE6C | |
| SCHEMBL31409528 | 0.66 | ADAM17 (0.48) | ESR1ESR2MEN1KMT2AHSP90AA1 | |
| SCHEMBL20450049 | 0.64 | PDE5A (0.38) | PDE5APDE6C | |
| SCHEMBL7464904 | 0.62 | ESRRB (0.45) | ESRRBESRRAESR1ESR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152612-A1 | NOVEL PHOSPHODIESTERASE INHIBITORS AND USES THEREOF | PDE5A, PDE2A, PDE3A | PDE5A 1/4885PDE6C 22/4885ESRRB 4017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.